Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Deciphera Pharmaceuticals (NASDAQ: DCPH) will participate in fireside chats at two investor conferences: Jefferies Healthcare Conference on June 9, 2022, and JMP Securities Life Sciences Conference on June 15, 2022. Both events will take place in New York, NY, starting at 10:00 AM ET. A live webcast will be available on the company's investor website and will be archived for 90 days. Deciphera focuses on developing medicines for cancer, including its approved product QINLOCK.

WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that members of the management team will participate in fireside chats at the following investor conferences:

• Jefferies Healthcare Conference on June 9, 2022 at 10:00 AM ET in New York, NY
• JMP Securities Life Sciences Conference on June 15, 2022 at 10:00 AM ET in New York, NY

A live webcast of both events will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. A replay of both webcasts will be archived on the Company’s website for 90 days following the presentation.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK^® is Deciphera’s switch control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005293/en/

Investor Relations:

Maghan Meyers

Argot Partners

Deciphera@argotpartners.com

212-600-1902



Media:

David Rosen

Argot Partners

david.rosen@argotpartners.com

212-600-1902

Source: Deciphera Pharmaceuticals, Inc.

FAQ

When is Deciphera Pharmaceuticals presenting at the Jefferies Healthcare Conference?

Deciphera Pharmaceuticals will present at the Jefferies Healthcare Conference on June 9, 2022, at 10:00 AM ET.

What is the location of the JMP Securities Life Sciences Conference?

The JMP Securities Life Sciences Conference will be held in New York, NY on June 15, 2022, at 10:00 AM ET.

Where can I watch the Deciphera Pharmaceuticals investor conference webcasts?

Live webcasts of the Deciphera Pharmaceuticals investor conferences can be viewed on their Events and Presentations page.

What is QINLOCK and where is it approved?

QINLOCK is Deciphera's switch control inhibitor approved for fourth-line GIST, available in multiple countries including the US, EU, Canada, and Australia.

What is the focus of Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals focuses on discovering and developing innovative medicines for cancer treatment.